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ABSTRACT
Objectives To describe the epidemiology of
coronary heart disease (CHD) in England and the
activity of primary healthcare teams in managing
patients with CHD, and also to demonstrate the
utility of computerised patient records in providing
access to epidemiological data and data reflecting
healthcare activity.
Design A descriptive survey of CHD and related
clinical data, recorded using computerised clinical
records, entered by primary healthcare teams.
Aspects reported include prevalence of CHD,
together with additional data reflecting clinical
monitoring activity, therapeutic interventions and
comorbidity in patients affected by CHD.
Setting 317 general practices in 23 English primary
care trusts (PCTs).
Data acquisition MIQUEST was used to interro-
gate 2 252 274 computerised patient records. Data
were extracted in the form of sex and age aggregated
counts of patients meeting a range of extraction
criteria.
Results The observed crude prevalence of CHD is
40.3 per 1000 (males 46.6, females 34.2). A variety
of findings are presented relating to the treatment,
monitoring and comorbidities of CHD. Significant
and systematic gender inequalities are demonstrated
to exist in the monitoring and treatment of CHD.
Conclusions Extraction of data from computer-
ised patient records is a valuable and practicable
method of generating information to inform clin-
icians and National Health Service (NHS) organ-
isations. Systematic gender disparities exist in the
care delivered to patients with CHD.
Summary points
 CHD affects approximately 4% of the population
in England. A significant gender gradient exists
with approximately 4.7% of males being affected
and 3.4% of females.
 This study provides persuasive confirmatory
evidence of previously demonstrated gender dis-
parities in the monitoring and treatment of
CHD. The data also strongly support the sugges-
tion that such gender disparities are systematic in
nature.
 The study provides evidence of feasibility and
potential value of remote interrogation of com-
puterised clinical records in primary care to
provide detailed information about population
health characteristics and clinical activity to both
the clinical community and NHS organisations.
Keywords: clinical care, coronary heart disease,
electronic patient records, gender inequalities
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Introduction
The National Service Framework for Coronary Heart
Disease (NSF) identifies coronary heart disease
(CHD) as a major cause of preventable mortality and
morbidity in England.1 In addition, regionally and
socio-economically determined variability in mor-
bidity, mortality and intervention rates are described
as ‘unacceptable’ and an explicit commitment is made
to eradicating this ‘postcode lottery of care’. The NSF
sets a wide range of national standards, milestones,
goals and performance measures through which the
National Health Service (NHS) is required to respond
to these challenges. The NSF explicitly requires NHS
organisations to produce evidence of effective inter-
vention.
Primary Care Information Services (PRIMIS) is a
training and support service delivered to primary
healthcare teams in general practice and to primary
care trusts (PCTs) by a specialist team based in the
Division of Primary Care at the University of
Nottingham.2 The objective of PRIMIS is to encour-
age general practice teams to make greater and more
effective use of computerised patient records systems
to support quality improvement in the delivery of
clinical care. PRIMIS is configured on a cascade train-
ing basis and the resources of the service are made
available to general practices through locally (usually
PCT-) based information facilitators. To complement
the training and support service PRIMIS also under-
takes extraction, analysis and feedback of data from
general practitioners’ computerised records systems.
Data extractions are configured to examine the quality
of data and also to support comparative analysis against
a range of recognised clinical guidelines.3 In this latter
category, PRIMIS has undertaken comparative analyses
based on the recommendations of the NSF for CHD
in January 2001 and May 2002 (a further extraction
took place in 2003, and the results of this are in the
process of analysis and interpretation).
This paper reports an analysis of data extracted
from general practice computerised records systems in
May 2002 for the PRIMIS CHD comparative analysis.
The data reported reflect various aspects of the epi-
demiology and management of CHD.
Methods
Participants
A total of 317 general practices in 23 PCTs in England.
Participating PCTs were widely spread geographically
and included both rural areas and urban centres in
the north, Midlands and south of England.
Eligibility criteria
All general practices and PCTs participated in the
comparative analysis on a volunteer basis. No attempt
was made to control for geographical location or
socio-economic factors.
Data collection
Data were extracted from computerised patient
records systems using the data extraction utility
MIQUEST.4 The data extracted were determined by a
specification of criteria derived from the NSF for
CHD and published on the PRIMIS website.5 Data
extraction was undertaken during May 2002 and
involved interrogation of a total of 2 252 274 patient
records. Data were extracted in the form of counts of
patients meeting a range of extraction criteria broken
down by sex and five-year age bands.
Analysis
Statistical analyses were undertaken using Stats-
Direct™ version 2.2.3. Where appropriate, direct
standardisation of data was undertaken using the
European standard population.
Results
Prevalence of CHD
Overall crude and standardised prevalence rates for
CHD are presented in Table 1. The observed crude
prevalence rate for CHD is 40.3 per 1000 (males 46.6,
females 34.2) and the standardised rate is 31.3 per
1000 (males 40.3, females 23.2). Chi-square tests of
the gender differences for both crude and standardised
rates are both highly significant (P 0.0001). Data
derived from the General Practice Research Database
(GPRD) are also presented in Table 1 for comparison.6
The data from GPRD refer to treated CHD and are
therefore not strictly equivalent to the data obtained
by PRIMIS, which includes all patients irrespective of
their treatment status. Table 2 presents the prevalence
data derived by PRIMIS aggregated to PCT level 
and demonstrates the high level (up to fivefold) of
variation in crude prevalence rates between par-
ticipating PCTs. Standardisation of these data results
in a marked reduction in observed variation. These
observations are further illustrated in Figures 1 
and 2.
Treatment of CHD
Table 3 presents analyses of treatment interventions
with statins and aspirin recorded during the 12-month
period immediately preceding data extraction in the
population with a record of CHD. Additional data 
are presented representing those patients with CHD
but without a record of either intervention. Overall
rates have been calculated using data pooled from all
sources and the descriptive statistics reported (mean,
range and interquartile range) reflect analysis of data
aggregated at the level of each participating PCT.
Evidence for statin treatment in the previous year 
was found in 45.4% of patient records (males 49.9%,
females 39.5%) and evidence for aspirin prophylaxis
(including evidence of self-medication by patients) 
in 68.8% (males 71.5%, females 65.1%). No data were
extracted relating to contraindications or adverse
reactions to either statins or salicylates. Patients for
whom there was no evidence of either intervention
represented 23.4% (males 20.4%, females 27.5%). All
gender differences detected were present system-
atically across all 23 PCTs (as illustrated by Figure 3)
and statistical analysis of these differences using chi-
square tests consistently produced P values 0.0001.
Further analysis of these data using the Mantel-
Haenszel technique revealed no loss of statistical sig-
nificance attributable to differences in age stratification
between the two gender groups.
Clinical monitoring of patients 
with CHD
These data, all of which refer to records created in 
the 12-month period preceding data extraction, are
summarised in Table 4: 74.0% (males 74.3%, females
73.7%, P=0.07) of patients have a recorded blood
pressure reading; 35.0% (males 37.0%, females 32.3%,
P 0.0001) have a record of body mass index; 49.7%
(males 53.6%, females 44.5%, P 0.0001) have a serum
cholesterol value recorded and 37.9% (males 39.8%,
females 35.3%, P 0.0001) have had their smoking
status recorded. Gender differences were again present
systematically across all PCTs. Re-analysis using the
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Table 1 Prevalence of CHD
PRIMIS May 2002 Key health statistics 1998 
(all CHD) (treated CHD)
Subjects CHD Subjects CHD
Absolute numbers All 2 252 274 90 873 1 202 819 44 707
Male 1 117 400 52 053 594 831 24 986
Female 1 134 874 38 820 607 988 19 721
Rate/1000 95% CI P (c2) Rate/1000 95% CI
CHD: crude rates All 40.3 40.1–40.6 37.2 36.8–37.5
Male 46.6 46.2–47.0 0.0001 42.0 41.5–42.5
Female 34.2 33.9–34.5 32.4 32.0–32.9
CHD: standardised rates All 31.3 31.1–31.6 n/a n/a
Male 40.3 40.0–40.7 0.0001 37.2 36.8–37.6
Female 23.2 22.9–23.5 21.9 21.5–22.2
Table 2 Prevalence data for CHD aggregated to PCT level
Mean Range Interquartile range
CHD: crude rates All 41.4 21.6–99.8 33.2–35.8
Male 48.3 24.3–108.5 39.7–52.3
Female 34.8 18.7–92.2 27.3–40.0
CHD: standardised rates All 30.4 21.7–45.4 26.6–35.6
Male 39.4 29.6–55.7 35.0–45.1
Female 22.2 14.2–37.6 18.5–26.1
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Figure 1 Crude prevalence of CHD in 23 PCTs
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Figure 2 Standardised prevalence of CHD in 23 PCTs
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Mantel-Haenszel technique revealed a probable age-
stratification effect in the recording of blood pressure
readings only.
Presence of comorbidities 
in patients with CHD
Analyses of comorbidity with CHD of heart failure,
transient ischaemic attack or stroke disease, atrial
fibrillation, peripheral vascular disease, diabetes
mellitus and hypertension are detailed in Table 5.
Heart failure was present in 11.0% (males 10.1%,
females 12.3%, P 0.0001); transient ischaemic attack
(TIA) or stroke disease present in 10.0% (males 9.6%,
females 10.5%, P 0.0001); atrial fibrillation present
in 8.4% (males 8.1%, females 8.7%, P=0.0006);
peripheral vascular disease present in 3.9% (males
4.5%, females 3.2%, P 0.0001); diabetes present in
14.6% (males 15.3%, females 13.7%, P 0.0001) and
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Table 3 Recording of treatment offered to patients with CHD
n=90 873 Mean Range Interquartile Overall 95% CI
range rate (%) 
(data aggregated at PCT level) (pooled 
data)
Evidence of All 45.3 27.6–55.7 40.6–50.5 45.4 45.1–45.8
treatment with Male 49.8 32.6–59.5 46.8–55.0 49.9 49.4–50.3 0.0001 0.0001
a statin (%) Female 39.0 20.0–49.6 34.2–43.7 39.5 39.0–40.0
Evidence of All 66.9 48.3–74.3 65.1–72.2 68.8 68.5–69.1
treatment with Male 69.4 49.9–76.3 66.6–75.0 71.5 71.1–71.9 0.0001 0.0001
aspirin (%) Female 63.5 46.4–71.7 60.8–67.8 65.1 64.6–65.5
No evidence of All 24.0 17.6–38.1 21.2–25.1 23.4 23.1–23.7
treatment with Male 21.0 15.9–34.9 18.5–22.9 20.4 20.0–20.7 0.0001 0.0001
either statin Female 28.1 20.5–44.3 25.3–29.3 27.5 27.0–28.0
or aspirin (%)
Figure 3 Evidence of treatment of patients with CHD with a statin in the previous year
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Table 4 Recording of clinical monitoring data in records of patients with CHD
n=90 873 Mean Range Interquartile Overall 95% CI
range rate (%) 
(data aggregated at PCT level) (pooled 
data)
Blood pressure All 72.1 37.7–85.6 68.4–79.9 74.0 73.7–74.3
recorded in Male 72.0 37.9–85.6 67.7–79.5 74.3 73.9–74.6 0.07 0.0001
last year (%) Female 72.2 37.4–86.6 67.9–80.0 73.7 73.3–74.1
Body mass index All 32.9 17.7–48.2 27.0–39.0 35.0 34.7–35.3
recorded in Male 34.5 17.2–52.8 27.1–41.8 37.0 36.5–37.4 0.0001 0.0001
last year (%) Female 30.8 18.3–41.9 24.5–37.3 32.3 31.8–32.8
Serum cholesterol All 47.0 22.9–62.5 39.5–55.8 49.7 49.4–50.1
recorded in Male 50.6 24.6–65.4 43.0–59.3 53.6 53.2–54.0 0.0001 0.0001
last year (%) Female 42.0 20.4–58.0 36.1–51.9 44.5 44.0–45.0
Smoking status All 35.6 18.3–45.9 31.6–42.3 37.9 37.5–38.2
recorded in Male 37.1 19.9–48.6 31.4–42.8 39.8 39.3–40.2 0.0001 0.0001
last year (%) Female 33.6 15.2–43.8 29.9–40.3 35.3 34.9–35.8
P
(c2) (Mantel-
Haenszel)
Table 5 Comorbidities in patients with CHD
n=90 873 Mean Range Interquartile Overall 95% CI
range rate (%) 
(data aggregated at PCT level) (pooled 
data)
Comorbidity of All 11.1 3.4–20.0 9.4–12.6 11.0 10.8–11.2
heart failure (%) Male 10.2 3.9–17.7 8.8–11.4 10.1 9.8–10.4 0.0001 0.03
Female 12.3 2.7–23.4 10.3–14.4 12.3 12.0–12.6
Comorbidity of All 10.0 6.4–17.0 8.4–11.0 10.0 9.8–10.2
TIA or stroke Male 9.7 4.6–14.6 8.5–11.2 9.6 9.3–9.8 0.0001 0.0007
disease (%) Female 10.6 6.2–20.6 9.1–11.4 10.5 10.2–10.8
Comorbidity of All 8.4 5.5–11.1 7.2–9.7 8.4 8.2–8.6
atrial fibrillation Male 8.0 5.6–11.5 6.7–9.2 8.1 7.9–8.3 0.0006 0.0001
(%) Female 8.8 5.3–11.6 7.8–9.8 8.7 8.5–9.0
Comorbidity of All 3.1 0.1–6.0 2.0–4.1 3.9 3.8–4.1
peripheral Male 3.5 0–6.9 2.0–4.9 4.5 4.3–4.7 0.0001 0.0001
vascular disease Female 2.5 0.2–4.8 1.8–3.2 3.2 3.0–3.3
(%)
Comorbidity of All 15.0 12.0–19.3 13.5–16.5 14.6 14.4–14.8
diabetes (%) Male 15.6 12.5–20.6 13.8–17.1 15.3 15.0–15.6 0.0001 0.0001
Female 14.2 10.1–18.3 12.5–16.2 13.7 13.4–14.1
Comorbidity of All 41.5 23.6–52.9 37.6–44.7 40.7 40.3–41.1
hypertension (%) Male 37.8 20.5–49.6 34.2–41.0 36.8 36.4–37.2 0.0001 0.0001
Female 46.7 28.6–56.3 43.1–50.3 46.0 45.5–46.5
P
(c2) (Mantel-
Haenszel)
hypertension in 40.7% (males 36.8%, females 46.0%,
P 0.0001). Analysis of these data using the Mantel-
Haenszel test was notable only in relation to the presence
of heart failure where the P value increased to 0.03.
The study team are aware of issues affecting the
representation of peripheral vascular disease using
Read codes and consider that the data extracted
represents a significant underestimate of the true
prevalence of this condition.
Strengths and limitations 
of this study
Data quality
No attempt has been made to evaluate the quality of
the data that have been returned by practices. Measure-
ment of the quality of clinical data without the benefit
of detailed contextual knowledge (such as access to
the source record and recording clinician) is, at best,
an inexact science and the potential additional value
to be achieved was felt to be low. However, previous
studies have shown the accuracy and positive predic-
tive value of data recorded in general practice com-
puter systems to be very high.7,8 Data published by
PRIMIS have indicated that data quality in general
practice systems is improving with time.3
Selection bias
Participating PCTs and general practices were
recruited on a volunteer basis. In addition, because of
the anonymous nature of PRIMIS comparative analysis
activities, no information about the characteristics 
of the participating PCTs or their patients is known 
to the study team. Hence it has not been possible to
eliminate or control for bias resulting from the self-
selection of participants.
Sample size
The number of patient records interrogated represents
over 4.5% of the English population.9 The reliability
and validity of the conclusions can be anticipated to
be significantly enhanced as a result of the scale of the
study.
Geographical spread
The study includes PCTs from a wide diversity of
locations encompassing rural, semi-rural and urban
locations in the north, Midlands and south of England.
This degree of diversity is likely to contribute to the
extent to which the study is representative.
Overall the study team consider that the data
collected are highly likely to be representative of the
population of England.
Discussion
In terms of the numbers of participating general
practices and patient records interrogated, this survey
represents one of the largest exercises of its kind ever
to be undertaken. As such, despite the weaknesses
outlined above, it can be considered to be an inform-
ative representation of the epidemiology of CHD and
associated disorders encountered in primary care in
England. In addition, it provides valuable insight into
the response of English general practices to the service
demands that CHD poses.
The prevalence of CHD reflected in these data is
entirely consistent with that reported elsewhere,
although other sources of similar data (such as the
British Heart Foundation statistics database) are not
directly comparable because they focus on denominator
groups which are subsets of the total population, or,
alternatively, they focus on treated CHD rather than
CHD in its entirety.7,10 Despite that limitation there is
no aspect of the data presented here that suggests
incompatibility with other sources of epidemiological
data.
One of the most striking findings of this study is
the pronounced gender disparities that are evident 
in both the treatment and monitoring of established
CHD. Bouvy et al. in the Netherlands and Hippisley-
Cox et al. in the United Kingdom (UK) have both
previously reported this phenomenon in primary
care.11,12 The data presented here provide persuasive
reinforcement of these earlier findings and strong
evidence to support the suggestion by Hippisley-Cox
of the existence of a systematic gender bias in the
monitoring and management of CHD in the UK.
The data presented also demonstrate marked
regional variations in the epidemiology of CHD.
A fivefold disparity between geographical locations 
is demonstrated; this is, in part, accounted for by
variation in demographic characteristics. It is highly
probable that similar variations in demographic and
socio-economic characteristics also exist at an intra-
locality level. The magnitude of these variations will
significantly complicate any attempt to compare
clinical activity data at both inter- and intra-locality
level. It is clear that, while this study demonstrates the
utility of data extraction for the purposes of inter-
and intra-locality comparisons, analysis of such data
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requires considerable caution and full knowledge of
the characteristics of all localities involved.
Conclusions
The use of data extraction techniques to access data
from electronic patient records has been demon-
strated to be a practicable approach to the generation
of detailed information about population health
characteristics and also about clinical activity in
response to morbidity. This information is potentially
of value to clinicians in pursuit of quality improvement
and to healthcare organisations needing to monitor
population health needs and healthcare activity.
CHD affects approximately 4% of the population
with a significant excess in the male population. In
contrast there is evidence of a significant systematic
gender bias in favour of male patients in the mon-
itoring and treatment of established CHD.
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